Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hassan Asghar

Dentist, Periodontics Seven Points, TX Doctor of Dentistry

NPI 1609302553 CMS profile 3659817

606 S Seven Points Dr Ste 2, Seven Points, TX 75143

Open in the dashboard

General payments

$16,519

165 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hassan Asghar of Seven Points, TX is reported in the CMS Open Payments database as having received $16,519 across 165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Dentist, Periodontics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,657 13
2024 General $507 13
2023 General $148 4
2022 General $3,690 36
2021 General $3,496 61
2020 General $989 28
2019 General $1,031 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hassan Asghar
  • Dentist, Periodontics median
  • Middle half of Dentist, Periodontics
  • National median

In program year 2025, general payments to Hassan Asghar were reported at $6,657. Among 2,732 Dentist, Periodontics profiles paid that year, the median was $112 and the middle half received between $42 and $307.

Show as a table
Year Hassan Asghar Dentist, Periodontics median Middle half National median
2019 $1,031 $129 $42–$367 $163
2020 $989 $90 $35–$265 $114
2021 $3,496 $125 $42–$411 $132
2022 $3,690 $123 $43–$364 $149
2023 $148 $125 $45–$358 $160
2024 $507 $119 $42–$350 $164
2025 $6,657 $112 $42–$307 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimvie Inc. $7,288 30 payments
  2. Keystone Dental Inc. $5,101 47 payments
  3. Straumann USA LLC $1,911 16 payments
  4. BioHorizons Implant Systems Inc. $1,477 47 payments
  5. Zimmer Biomet Holdings, Inc. $334 12 payments
  6. Philips Electronics North America Corporation $260 8 payments
  7. Relievant Medsystems, Inc. $40 1 payment
  8. Dentsply Sirona Inc $37 1 payment
  9. Carestream Dental, LLC $32 1 payment
  10. OraPharma, a division of Bausch Health US, LLC $23 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,080 2 payments
  2. Entertainment $4,456 43 payments
  3. Food and Beverage $3,931 104 payments
  4. Travel and Lodging $1,133 2 payments
  5. Education $816 12 payments
  6. Gift $103 2 payments
Products named General payments · program years 2019–2025
  1. RegenerOss Resorbable Xenograft $4,074 3 payments
  2. BioMend $3,930 1 payment
  3. OSSEOTITE NT $2,150 1 payment
  4. BioHorizons Dental Implants $1,150 27 payments
  5. TSX Implants $429 11 payments
  6. BioHorizons Dental Implants- TRX3812 $200 14 payments
  7. BioHorizons Dental Implants- BTA4212 $200 14 payments
  8. BioHorizons Dental Implants- BTA4210 $200 14 payments
  9. BioHorizons Dental Implants- TRX4610 $200 14 payments
  10. BioHorizons Dental Implants- TRX3810 $200 14 payments
  11. Other $1,886 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

938

Median for Dentist: 47

Drug cost

$3,519

Median for Dentist: $159

Branded share of claims

31.2%

Median for Dentist: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 208 $1,159
Methylprednisolone Generic 145 $953
Ibuprofen Generic 224 $507
Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen Brand 68 $210
Tramadol Hcl Generic 108 $195
Azithromycin Generic 48 $161
Amoxicillin Generic 65 $108
Clindamycin Hcl Generic 17 $87
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 17 $74
Chlorhexidine Gluconate Generic 13 $46

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 110,731 Part D prescribers listed as Dentist; they describe a distribution and say nothing about conduct.

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dentist, Periodontics in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record